Brief: AIM Vaccine Says Unit Got Clinical Trial Approval For EV71-CA16 Bivalent HFMD Vaccine Candidate
31/10/2022 01:37
Oct 31 (Reuters) - AIM Vaccine Co Ltd 6660.HK :
* UNIT GOT CLINICAL TRIAL APPROVAL FOR EV71-CA16 BIVALENT
HFMD
VACCINE CANDIDATE BY NMPA
Further company coverage: 6660.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine